# TPM Regimen (Thalidomide, Prednisone and Methotrexate) in LGLL

> **NCT04453345** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 42 (estimated)

## Conditions studied

- T-LGL Leukemia
- Clpd-Nk

## Interventions

- **DRUG:** thalidomide + prednisone + methotrexate

## Key facts

- **NCT ID:** NCT04453345
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-05-20
- **Primary completion:** 2023-05-20
- **Final completion:** 2025-05-20
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2020-07-01

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04453345

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04453345, "TPM Regimen (Thalidomide, Prednisone and Methotrexate) in LGLL". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04453345. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*